Phase 4 N=164 Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair
Analgesia, Postoperative
Primary: Cumulative Opioid Requirements for 72 Hours After Surgery — 325; 350; 310 mg morphine equivalents/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Metastatic Cancer · Solid Tumor · Lymphoma
Primary: Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria. — 0; 0; 0; 0 Number of DLTs
Phase 3 N=19 Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
Schizophrenia · Medication Nonadherence · Schizo Affective Disorder
Primary: Tablets Routine Questionnaire (TRQ) — -57; -23 percentage of change in adherence
N/A N=52 Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias
Ventricular Arrythmia
Primary: Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months — 8; 4; 5; 2 Participants
Phase 3 N=52 Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus
Vulvar Lichen Sclerosus
Primary: Change in SkinDEX-29 Score — -16.83; -5.92 score on a scale — p=0.007
N/A N=431 Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)
Prostate Cancer
Primary: Adaptive Coping — -0.089; -0.013 score on a scale — p=.9634
N/A N=411 Family Based Prevention of Alcohol and Risky Sex for Older Teens
Alcohol Drinking · Alcohol Intoxication · Alcohol Poison
Primary: Number of Teens Using Any Alcohol During Past 6 Months — 16; 20; 38; 14 Participants — p=<0.01
Phase 2 N=56 Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
Pain · Inflammation
Primary: Assessment of Pain — 30; 13; 2; 0 Participants
N/A N=13 Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture
Major Depressive Disorder
Primary: Change From Baseline Score of the Sheehan Disability Scale Through 6 Weeks — -3.57; -1.5; -2.29; -1.0 units on a scale — p=.05
Phase 4 N=10 Remission Through Early Monitored Insulin Therapy - Duration Month
Type 2 Diabetes Mellitus
Primary: Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months — 9.00; 6.81; 7.13; 7.26 percentage of glycosylated hemoglobin
Phase 3 N=74 Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Erythropoietic Protoporphyria
Primary: The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0)…
Phase 2 N=310 A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicity (DLT) — 1; 4; 3 Participants
Phase 3 N=279 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
Non-Germline BRCA Mutated Ovarian Cancer
Primary: Progression Free Survival (PFS) — 9.2 months
Phase 4 N=10 Sphenopalatine Ganglion Blocks RCT
Migraine
Primary: Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment — 3; 1; 1; 0 participants
Phase 2 N=135 A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
Hypertension
Primary: Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28 — 1.38; -1.42; -3.28; -5.59…